Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) remain at increased cardiovascular residual risk and endothelial dysfunction, even after optimizing metabolic control and treatment by sodium-glucose-2 transporter inhibitors (SGLT2-is). The present study was based on the hypothesis that prop...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ther Adv Chronic Dis
Autores principales: Breder, Ikaro, Cunha Breder, Jessica, Bonilha, Isabella, Munhoz, Daniel B., Medorima, Sheila T. Kimura, Oliveira, Daniela C., do Carmo, Helison R., Moreira, Camila, Kontush, Anatol, Zimetti, Francesca, Zanotti, Ilaria, Carvalho, Luiz Sergio F., Nadruz, Wilson, Muscelli, Elza, Quinaglia, Thiago, Sposito, Andrei C.
Formato: Artigo
Lenguaje:Inglês
Publicado: SAGE Publications 2020
Materias:
Study Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7534094/
https://ncbi.nlm.nih.gov/pubmed/33062236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622320959248
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares